Septerna (SEPN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 26, 2026, with voting on director elections and auditor ratification.
Stockholders of record as of April 29, 2026, are eligible to vote; 44,949,189 shares outstanding.
Proxy materials are distributed via Internet to reduce costs and environmental impact, with printed copies available upon request.
The company qualifies as an “emerging growth company” and provides scaled disclosures.
Voting matters and shareholder proposals
Two Class II directors are up for election to serve until 2029.
Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026 is on the agenda.
Shareholders may submit proposals for the 2027 meeting between February 26 and March 28, 2027.
Board recommends voting “FOR” all director nominees and auditor ratification.
Board of directors and corporate governance
Board consists of eight members divided into three staggered classes.
Majority of directors are independent per Nasdaq and SEC rules.
Four standing committees: audit, compensation, nominating and corporate governance, and research and development.
Board leadership is separated between CEO and Chairman roles.
Directors are expected to attend at least 75% of meetings and annual meetings.
Latest events from Septerna
- Virtual annual meeting to vote on director elections and auditor ratification.SEPN
Proxy filing30 Apr 2026 - SEP-631 advances to phase II for urticaria after strong phase I data; SEP-479 nears phase I start.SEPN
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Rapidly advancing oral GPCR therapies with strong pipeline and Novo Nordisk partnership.SEPN
Corporate presentation16 Mar 2026 - Pipeline advances and improved financials set stage for clinical milestones in 2026.SEPN
Q4 20259 Mar 2026 - SEP-631 showed strong Phase 1 safety and efficacy, advancing to Phase 2 urticaria trials in 2026.SEPN
Study result2 Mar 2026 - Lead GPCR programs advance toward clinical milestones, supported by strong platform and partnerships.SEPN
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Advancing oral GPCR-targeted therapies with strong clinical pipeline and Novo Nordisk partnership.SEPN
Corporate presentation13 Jan 2026 - GPCR platform drives rapid pipeline growth, with SEP786 and SEP631 clinical data expected in 2025.SEPN
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - SEP-479, a next-gen oral PTH1R agonist, advances with improved efficacy and safety profile.SEPN
Cantor Global Healthcare Conference 20255 Jan 2026